vertex stock forecast

Get the latest Vertex Pharmaceuticals Incorporated VRTX detailed stock quotes, stock data, Real-Time ECN, … MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Vertex Pharmaceuticals has received 64.31% “outperform” votes from our community. The P/E ratio of Vertex Pharmaceuticals is 27.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 39.80. 92.17% of the stock of Vertex Pharmaceuticals is held by institutions. Identify stocks that meet your criteria using seven unique stock screeners. Vertex Pharmaceuticals, Inc. (VRTX) Stock Earning Per Share (EPS) Forecast / Estimate $ 2.828 The average consensus EPS for VRTX is $ 2.828 with a high estimate of $ 3.224 and Low of $ … Compare Top Brokerages Here. Exploring Vertex Pharmaceuticals (NASDAQ:VRTX) stock? There are 2 price predictions issued for Vertex Pharmaceuticals that average $252.00. Vertex Energy. View institutional ownership trends for Vertex Pharmaceuticals. VP & Chief Admin., Legal and Bus. The Vertex Pharmaceuticals Incorporated stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Officer, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, Spain: Police bust major drug distribution network in Madrid, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Interesting VRTX Put And Call Options For April 30th, Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes, Vertex Reports FDA Fast Track Designation For VX-880 - Quick Facts, Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes, 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry, Barron's Latest Picks And Pans: Lowe's, Microsoft, Vertex Pharmaceuticals, ViacomCBS And More. 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee. Should You Take Comfort From Insider Transactions At Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. High institutional ownership can be a signal of strong market trust in this company. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Vote “Underperform” if you believe VRTX will underperform the S&P 500 over the long term. The average Vertex Pharmaceuticals stock price prediction forecasts a potential downside of N/A from the current VRTX share price of $214.29. Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. The company's average rating score is 2.88, and is based on 21 buy ratings, 4 hold ratings, and no sell ratings. VRTX stock forecast Our latest prediction for Vertex Pharmaceuticals, Inc.'s stock price was made on the July 10, 2020 when the stock price was at 294.45$.. Looking for new stock ideas? Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside. Export data to Excel for your own analysis. View our full suite of financial calendars and market data tables, all for free. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Top institutional investors include BlackRock Inc. (9.33%), Price T Rowe Associates Inc. MD (7.55%), FMR LLC (5.05%), Alliancebernstein L.P. (3.05%), Clearbridge Investments LLC (1.64%) and Janus Henderson Group PLC (1.60%). Vertex Pharmaceuticals (VRTX) stock price prediction is 374.656459 USD. Want to see which stocks are moving? Their forecasts range from $1.50 to $4.00. Is Vertex a Great Value Stock to Add to Your Portfolio? Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared. You may vote once every thirty days. VRTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, BlackRock Inc., Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, First Trust Advisors LP, Bank of New York Mellon Corp, and AMF Pensionsforsakring AB. The … A Warner Media Company. Vertex Pharmaceuticals (NASDAQ:VRTX) is the blueprint for a growing pharmaceutical stock. The 12-month stock price forecast … Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Vertex Pharmaceuticals declared that its board has approved a share repurchase plan on Wednesday, July 31st 2019, which authorizes the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. Vertex Stock Fell After a Setback on a New Drug. Devel. view top-rated stocks among Wall Street analysts, Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Receive Analysts' Upgrades and Downgrades Daily. During the same quarter in the previous year, the company posted $1.70 EPS. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks. Vertex Pharmaceuticals Inc Stock Forecast. All rights reserved. Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. View which stocks have been most impacted by COVID-19. Factset: FactSet Research Systems Inc.2019. See Vertex Pharmaceuticals Incorpor (VRTX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks. Skip to content. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. Find real-time VTNR - Vertex Energy Inc stock quotes, company profile, news and forecasts from CNN Business. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Vertex Pharmaceuticals does not have a long track record of dividend growth. Our Accessibility Statement The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex's stock is down 7.4% over the past year, while the S&P 500 has rallied 41.1%. This buyback authorization authorizes the company to purchase up to 1.2% of its shares through open market purchases. Vertex Pharmaceuticals' management team includes the following people: A terrifying (for some) and new disruptive force is creating thousands of new millionaires (Barron’s reports 20,000 to 200,000 so far) while at the same time destroying the financial future for many others. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. As of 2020 December 15, Tuesday current … Exec. VRTX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Janus Henderson Group PLC, Alliancebernstein L.P., Assenagon Asset Management S.A., UBS Asset Management Americas Inc., Swedbank, Amundi Pioneer Asset Management Inc., and Amundi Pioneer Asset Management Inc.. View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks. Vertex Pharmaceuticals has received a consensus rating of Buy. Vertex Pharmaceuticals was founded in 1989. Shares of VRTX can be purchased through any online brokerage account. Menu. © American Consumer News, LLC dba MarketBeat® 2010-2021. MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. S&P 500 3,943.34 Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Vertex Pharmaceutic is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock… Get the latest Vertex Pharmaceuticals (VRTX) stock price quote with real-time news, financials, charts and other important investing information. Fundamental company data provided by Zacks Investment Research. Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? View which stocks are hot on social media with MarketBeat's trending stocks report. The consensus among Wall Street analysts is that investors should "buy" Vertex Pharmaceuticals stock. See what's happening in the market right now with MarketBeat's real-time news feed. The stock price of Vertex Pharmaceuticals (VRTX) has seen a decline of 7% over the last five trading days, while it’s down 11% over the last ten trading days. This suggests a possible upside of 36.8% from the stock's current price. 2 analysts have issued twelve-month price targets for Vertex Energy's stock. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. According to analysts' consensus price target of $293.13, Vertex Pharmaceuticals has a forecasted upside of 36.8% from its current price of $214.33. This suggests a possible upside of 85.8% from the stock… All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Based on 14 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. Vote “Outperform” if you believe VRTX will outperform the S&P 500 over the long term. There are currently 4 hold ratings, 21 buy ratings and 1 strong buy rating for the stock.

Hummel Teamwear Ireland, Alexander Der Große Zitate, Basketball 2 Oder 3 Schritte, Handball-wm ägypten Zuschauer, Fisher-price Bausteine Mega Bloks, Burberry Parfum Damen 30 Ml, Cold Pack Gel,